Compare Twist Bioscience Corp (TWST) vs Wipro Limited (WIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Twist Bioscience Corp vs Wipro Limited — how do they compare? Twist Bioscience Corp trades at $123.01 (market cap $7.82B), while Wipro Limited trades at $1.98 (market cap $19.22B). The key difference: Wipro Limited is far larger — about 2.5× Twist Bioscience Corp's market cap, and Wipro Limited pays a 4.35% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| TWST | WIT | |
|---|---|---|
Market Cap | $7.82B | $19.22B |
Sector | Health | Technology |
52-Week High | $124.88 | $3.06 |
52-Week Low | $24.16 | $1.78 |
Enterprise Value | $7.75B | $17.30B |
Dividend Yield | — | 4.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Twist Bioscience (TWST) trades at $115.67, up 6.04% in the last session, with bullish technical signals from moving averages and a recent analyst upgrade. Revenue growth is strong, with fiscal 2026 Q3 revenue up 23% year-over-year to $118.4 million, though the company remains unprofitable with negative net income margins. A recent $300 million public offering at $96 per share indicates capital raising for expansion.
The outlook is mixed: robust revenue growth and high analyst buy ratings (78.57%) support upside potential, but persistent losses, cash burn, and high valuation ratios pose significant risks. Investors should weigh growth prospects against financial sustainability concerns.
WIT trades at $2.02, up 1.51% today, with a neutral technical signal and bearish moving average trend. The company reported a net income margin of 13.92% and ROE of 16.09% for 2025, with revenue of $890.88 billion. Recent earnings have missed expectations, but partnerships with Databricks and ServiceNow aim to drive AI-led growth. Cash flow from operations remains strong at $169.43 billion, supporting a $0.02 dividend.
The outlook is mixed: valuation ratios like P/E of 15.25 and EV/EBITDA of 7.83 appear reasonable, but earnings misses and competitive pressures pose risks. Analyst sentiment is cautious with only 19% buy ratings. Key opportunities include AI expansion, while risks involve client spending cuts and margin pressure from wage increases.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →About Wipro Limited
Wipro is a leading global IT services provider, with 175,000 employees. Based in Bengaluru, this India IT services firm leverages its offshore outsourcing model to derive over half of its revenue (57%) from North America. The company offers traditional IT services offerings: consulting, managed services, and cloud infrastructure services as well as business process outsourcing as a service.
Read more on WIT →
